Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A study of CLBS12 in critical limb ischemia due to arteriosclerosis obliterans or Buerger's disease
jRCT1080223694Completed
- Sponsor
- EPS Corporation
- Start
- Oct 2017
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Randomised, open-label trial of honubicistmut-L in chronic limb-threatening ischemia (CLTI), arteriosclerosis obliterans and Buerger disease (TAO) (3 arms), sponsored by EPS Corporation. Started Oct 2017; status: completed.
02
Drugs
honubicistmut-L
03
Conditions
chronic limb-threatening ischemia (CLTI)arteriosclerosis obliteransBuerger disease (TAO)
Beyond the preview
Go deeper on jRCT1080223694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080223694.